A. Taveras

发表

Exploring the role of bromine at C(10) of (+)-4-[2-[4-(8-chloro-3,10-dibromo- 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(R)-yl)-1-piperidinyl]-2- oxoethyl]-1-piperidinecarboxamide (Sch-66336): the discovery of indolocycloheptapyridine inhibitors of farnesyl protein transferase.

M. Snow, P. Weber, P. Kirschmeier, 2002, Journal of medicinal chemistry.

The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines.

W. R. Bishop, E. Maxwell, Marnie McGuirk, 2001, Experimental cell research.

Tricyclic Farnesyl Protein Transferase Inhibitors: Antitumor Activity and Effects on Protein Prenylation

W. R. Bishop, P. Kirschmeier, L. Armstrong, 2000 .

Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide region.

M. Dwyer, D. Rindgen, D. Lundell, 2009, Bioorganic & medicinal chemistry letters.

Fluoroalkyl alpha side chain containing 3,4-diamino-cyclobutenediones as potent and orally bioavailable CXCR2-CXCR1 dual antagonists.

M. Dwyer, D. Rindgen, D. Lundell, 2009, Bioorganic & medicinal chemistry letters.

3,4-Diamino-1,2,5-thiadiazole as potent and selective CXCR2 antagonists.

Junying Zheng, J. Fossetta, D. Lundell, 2009, Bioorganic & medicinal chemistry letters.

Synthesis and structure-activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonists.

M. Dwyer, D. Rindgen, J. Fossetta, 2008, Bioorganic & medicinal chemistry letters.

3,4-Diamino-2,5-thiadiazole-1-oxides as potent CXCR2/CXCR1 antagonists.

Junying Zheng, J. Baldwin, D. Rindgen, 2008, Bioorganic & medicinal chemistry letters.

Antitumor 8-chlorobenzocycloheptapyridines: a new class of selective, nonpeptidic, nonsulfhydryl inhibitors of ras farnesylation.

W. R. Bishop, M. Snow, P. Kirschmeier, 1997, Bioorganic & medicinal chemistry.

Disease Progression of WHIM Syndrome in an International Cohort of 66 Pediatric and Adult Patients

Shannon M. McNulty, J. Walter, H. Kanegane, 2022, Journal of Clinical Immunology.

C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists.

M. Dwyer, D. Rindgen, D. Lundell, 2007, Bioorganic & medicinal chemistry letters.

Pharmacological Characterization of Sch527123, a Potent Allosteric CXCR1/CXCR2 Antagonist

M. Billah, M. Dwyer, J. Fossetta, 2007, Journal of Pharmacology and Experimental Therapeutics.

Detection and structural characterization of ras oncoprotein-inhibitors complexes by electrospray mass spectrometry.

S. Liberles, J. Brown, M. Snow, 1997, Bioorganic & medicinal chemistry.

Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).

L. Silvian, D. Aivazian, Lin Zhang, 2011, Bioorganic & medicinal chemistry letters.

Pharmacological Characterization of Sch 527123 , a Potent Allosteric CXCR 1 / CXCR 2 Antagonist

M. Billah, M. Dwyer, J. Fossetta, 2007 .

Genotype–phenotype correlations in WHIM syndrome: a systematic characterization of CXCR4WHIM variants

R. Skerlj, A. Taveras, A. Badarau, 2022, Genes & Immunity.

Identification of pharmacokinetically stable 3, 10-dibromo-8-chlorobenzocycloheptapyridine farnesyl protein transferase inhibitors with potent enzyme and cellular activities.

W. R. Bishop, P. Kirschmeier, R. Doll, 1999, Journal of medicinal chemistry.

Synthesis and structure-activity relationships of new disubstituted phenyl-containing 3,4-diamino-3-cyclobutene-1,2-diones as CXCR2 receptor antagonists.

M. Czarniecki, D. Rindgen, Tara M Stauffer, 2008, Bioorganic & medicinal chemistry letters.

Ras oncoprotein inhibitors: the discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex.

L. Perkins, S. Liberles, J. Brown, 1997, Bioorganic & medicinal chemistry.

An enantioselective method for reductive alkylation of aromatic carboxylic acid derivatives. Examination of the factors that provide stereoselectivity

P. Sundararaman, M. Macielag, A. Taveras, 1988 .

Synthesis and photochemistry of spiro[2.5]octa-1,4-dien-3-ones. Reversible biradical formation and biradical-olefin cycloaddition

A. Taveras, A. Schultz, 1996 .

Structure-based design of 2,6,7-trisubstituted-7H-pyrrolo[2,3-d]pyrimidines as Aurora kinases inhibitors.

L. Silvian, N. Pathan, Lin Zhang, 2012, Bioorganic & medicinal chemistry letters.

The first intermolecular 2+2 photocycloadditions of 2,5-cyclohexadien-1-ones to alkenes

A. Taveras, A. Schultz, 1988 .

Acid-catalyzed rearrangement of methyl (2aα,4aβ,6aβ,7bβ)-2,2a,5,6,6a,7b-hexahydro-2a-hydroxy-4-methoxycyclobut[3,4] indeno[4,5-b]oxete-4a(7H)-carboxylate

A. Taveras, R. Kullnig, A. Schultz, 1990 .

Synthesis and structure-activity relationships of 3,4-diaminocyclobut-3-ene-1,2-dione CXCR2 antagonists.

M. Dwyer, J. Baldwin, L. Ozgur, 2006, Bioorganic & medicinal chemistry letters.

Tricyclic farnesyl protein transferase inhibitors: crystallographic and calorimetric studies of structure-activity relationships.

P. Weber, R. Doll, W. Windsor, 1999, Journal of medicinal chemistry.

Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist.

M. Dwyer, J. Baldwin, L. Ozgur, 2006, Journal of medicinal chemistry.

Sch-66336 (sarasar) and other benzocycloheptapyridyl farnesyl protein transferase inhibitors: discovery, biology and clinical observations.

C. Baum, P. Kirschmeier, A. Taveras, 2003, Current topics in medicinal chemistry.

Photorearrangement of 4-alkyl-4-alkoxy-2, 5-cyclohexadienones: synthesis of 4-(alkyldimethoxymethyl)cyclopent-2-en-1-ones

A. Taveras, 1988 .

Biological effects and mechanism of action of farnesyl transferase inhibitors.

W. R. Bishop, P. Kirschmeier, L. Armstrong, 2000, Chemical research in toxicology.

Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis.

B. Gallagher, V. Baragi, A. Taveras, 2012, Journal of medicinal chemistry.

(+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5, 6]cyclohepta[1,2-b]- pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamid e (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agent.

W. R. Bishop, P. Kirschmeier, L. Wang, 1998, Journal of medicinal chemistry.

Synthesis, SAR and biological evaluation of 1,6-disubstituted-1H-pyrazolo[3,4-d]pyrimidines as dual inhibitors of Aurora kinases and CDK1.

L. Silvian, N. Pathan, Lin Zhang, 2012, Bioorganic & medicinal chemistry letters.

Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.

Walter A. Korfmacher, W. R. Bishop, J. Catino, 1998, Cancer research.

Extra binding region induced by non-zinc chelating inhibitors into the S1' subsite of matrix metalloproteinase 8 (MMP-8).

R. Montanari, G. Pochetti, A. Taveras, 2009, Journal of medicinal chemistry.

Solid-state photochemistry. Remarkable effects of the packing of molecules in crystals on the diastereoselectivity of the intramolecular 2 + 2 photocycloaddition of a 4-(3'-butenyl)-2,5-cyclohexadien-1-one

F. Tham, A. Taveras, Richard E. Taylor, 1992 .

Discovery of 4-aminomethylphenylacetic acids as γ-secretase modulators via a scaffold design approach.

K. Rhodes, Lin Xu, D. Kocisko, 2011, Bioorganic & medicinal chemistry letters.

Intramolecular 2 + 2 photocycloadditions of 4-(3'-alkenyl)- and 4-(3'-pentynyl)-2,5-cyclohexadien-1-ones

A. Taveras, M. Plummer, R. Kullnig, 1988 .

A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models.

Christian Gege, Lixia Jin, Irving Sucholeiki, 2009, Arthritis and rheumatism.

Interaction of a novel GDP exchange inhibitor with the Ras protein.

J. Brown, M. Snow, C. Kissinger, 1998, Biochemistry.

Discovery of biaryl carboxylamides as potent RORγ inverse agonists.

N. Powell, L. Silvian, I. Enyedy, 2015, Bioorganic & medicinal chemistry letters.

Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with Waldenström's Macroglobulinemia with MYD88 and CXCR4 Mutations

M. Dimopoulos, C. Buske, V. Garg, 2021, Blood.

Discovery of BIIB042, a Potent, Selective, and Orally Bioavailable γ-Secretase Modulator.

K. Rhodes, Lin Xu, Tina Talreja, 2011, ACS medicinal chemistry letters.

Wavelength dependent photoisomerization of bicyclo[3.1.0]hexenones

W. G. Dauben, A. Taveras, A. Schultz, 1992 .

An improved procedure for the conversion of3,3-disubstituted-1,4-cyclohexadienes to 2,5-cyclohexadien-1-ones

R. Harrington, A. Taveras, A. Schultz, 1988 .

BIIB042, a novel γ-secretase modulator, reduces amyloidogenic Aβ isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer's disease

K. Rhodes, Lin Xu, Tina Talreja, 2016, Neuropharmacology.

A synthetically useful conversion of benzoic acid derivatives to 4-alkylphenols and 4-alkyl-3-carbalkoxyphenols

R. Harrington, M. Macielag, A. Taveras, 1987 .